{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T15:00:17Z","timestamp":1763564417181,"version":"3.41.2"},"reference-count":31,"publisher":"Informa UK Limited","issue":"8","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Anticancer Therapy"],"published-print":{"date-parts":[[2025,8,3]]},"DOI":"10.1080\/14737140.2025.2515989","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T04:26:21Z","timestamp":1748924781000},"page":"845-852","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Evaluation of sacituzumab govitecan for advanced\/metastatic non-small cell lung cancer"],"prefix":"10.1080","volume":"25","author":[{"given":"Irfan","family":"Cicin","sequence":"first","affiliation":[{"name":"Istinye University","place":["Istanbul, Turkey"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Berivan","family":"Karatekin","sequence":"additional","affiliation":[{"name":"Istanbul Aydin University","place":["Istanbul, Turkey"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esra","family":"G\u00fczelaltuncekic","sequence":"additional","affiliation":[{"name":"Istanbul Aydin University","place":["Istanbul, Turkey"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilker","family":"Kolbas","sequence":"additional","affiliation":[{"name":"Istanbul Aydin University","place":["Istanbul, Turkey"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2025,6,5]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21763"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13304-024-01841-3"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2020.1757067"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20150089"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.09.004"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.4318"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26237294"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2019.1632115"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.bioconjchem.5b00223"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.27766"},{"issue":"11","key":"e_1_3_5_14_1","first-page":"715","article-title":"A closer look at sacituzumab govitecan-hziy","volume":"18","author":"Bardia A","year":"2020","unstructured":"Bardia A. A closer look at sacituzumab govitecan-hziy. Clin Adv Hematol Oncol. 2020;18(11):715\u2013717.","journal-title":"Clin Adv Hematol Oncol"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-022-06660-x"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15235505"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920915980"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.21037\/atm-22-621"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-1764"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep33658"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.03.005"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-22-0375"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0272"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0933"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02767"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24119674"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14051238"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00774-2"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00733"},{"issue":"9","key":"e_1_3_5_30_1","first-page":"JCO2401544","article-title":"TROPION-Lung01 trial investigators. Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III TROPION-Lung01 study","volume":"42","author":"Ahn MJ","year":"2024","unstructured":"Ahn MJ, Tanaka K, Paz-Ares L, et al. TROPION-Lung01 trial investigators. Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III TROPION-Lung01 study. J Clin Oncol. 2024;42(9):JCO2401544.","journal-title":"J Clin Oncol"},{"key":"e_1_3_5_31_1","unstructured":"NCT05609968. Study of pembrolizumab (MK-3475) monotherapy versus sacituzumab govitecan in combination with pembrolizumab for participants with metastatic non-small cell lung cancer (NSCLC) with programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) \u226550% (MK-3475-D46). https:\/\/www.clinicaltrials.gov\/study\/NCT05609968"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2306434"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00329-7"}],"container-title":["Expert Review of Anticancer Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737140.2025.2515989","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T10:41:41Z","timestamp":1754044901000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737140.2025.2515989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,5]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,3]]}},"alternative-id":["10.1080\/14737140.2025.2515989"],"URL":"https:\/\/doi.org\/10.1080\/14737140.2025.2515989","relation":{},"ISSN":["1473-7140","1744-8328"],"issn-type":[{"type":"print","value":"1473-7140"},{"type":"electronic","value":"1744-8328"}],"subject":[],"published":{"date-parts":[[2025,6,5]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-12-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}